Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Withdrawn 1Terminated 1Recruiting 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Genitourinary 1CNS 1

Conditions

Carcinoma, Hepatocellular 7Neoplasms 2Urologic Neoplasms 1Thyroid Neoplasms 1Sarcoma, Kaposi 1Hepatitis B 1GBM 1Endometrial Neoplasms 1Cholangiocarcinoma 1Carcinoma, Renal Cell 1Carcinoma, Non-Small-Cell Lung 1Breast Neoplasms 1Brain Neoplasms 1Advanced Hepatocellular Carcinoma 1Acrocephalosyndactylia 1

Interventions

Radiosurgery 10Temozolomide 6Magnetic Resonance Spectroscopy 6pembrolizumab 3Trastuzumab 3Radiation 3fluciclovine F-18 2cabazitaxel 2Surgical Procedures, Operative 2Specimen Handling 2Radiotherapy 2Magnetic Resonance Imaging 2Erlotinib Hydrochloride 2Carboplatin 2Bevacizumab 2Aminolevulinic Acid 2tucatinib 1thymoglobulin 1tepotinib 1temsirolimus 1sodium thiosulfate 1ribociclib 1pazopanib 1patritumab deruxtecan 1palbociclib 1osimertinib 1neratinib 1lenvatinib 1irinotecan sucrosofate 1gancotamab 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Withdrawn × Brain Neoplasms × lenvatinib × Clear all
NCT07011849 2025-08-13

Study of Lenvatinib Plus Pembrolizumab in IO Refractory mRCC Patients With Brain Metastases

M.D. Anderson Cancer Center

Phase 2 Withdrawn
CNSGenitourinary

Brain Neoplasms, Carcinoma, Renal Cell

Data powered by HemOnc (CC BY 4.0) Colophon âš¡